trending Market Intelligence /marketintelligence/en/news-insights/trending/a7xo_qQycJKYAOipLtvCug2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Express Scripts provides FY'17 outlook

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Express Scripts provides FY'17 outlook

Express Scripts Holding Co. Inc. expects to achieve adjusted EPS of $6.82 to $7.02 for 2017.

The S&P Capital IQ normalized consensus EPS estimate for 2017 is $6.96.

Total adjusted claims for 2017 are projected to be in the range of $1.38 billion to $1.43 billion. EBITDA is expected to be between $7.31 billion to $7.51 billion, with cash flow from operations in the range of $4.70 billion to $5.20 billion.

Express Scripts Holding also updated its EPS guidance for 2016 to a range of $5.28 to $5.34, up from the previous guidance range of $4.47 to $4.53. The outlook update was driven by the impact from discrete tax benefits of 81 cents per share associated with the disposition of PolyMedica Corp.

Guidance for total adjusted claims for 2016 was updated to a range of $1.40 billion to $1.42 billion, compared to the previous range of $1.27 billion to $1.28 billion.

Express Scripts also reaffirmed its adjusted EPS guidance of $6.36 to $6.42 and EBITDA outlook of $7.23 billion to $7.33 billion for 2016.

The S&P Capital IQ normalized consensus EPS estimate for 2016 is $6.38.